Navigation Links
Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome
Date:12/29/2011

RARITAN, N.J., Dec. 29, 2011 /PRNewswire/ -- Janssen Research & Development, LLC (JRD) announced today that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of XARELTO® (rivaroxaban), an oral anticoagulant, to reduce the risk of (thrombotic) cardiovascular events in patients with Acute Coronary Syndrome (ACS).

The filing is supported by data from the pivotal Phase 3 ATLAS ACS 2 TIMI 51 (Anti-Xa Therapy to Lower cardiovascular events in Addition to aspirin with/without thienopyridine therapy in Subjects with Acute Coronary Syndrome) trial, which was presented in November at the American Heart Association Scientific Sessions and published in the New England Journal of Medicine (10.1056/NEJMoa1112277).

ACS is a complication of coronary heart disease, which is the leading cause of death in the U.S. and also one of the most prevalent non-communicable diseases in the world. ACS occurs when a blood clot blocks a coronary artery, reducing blood supply to the heart. This disruption of blood flow can cause a heart attack, or unstable angina, a condition signifying that a heart attack may soon occur. Each year, an estimated 1.2 million patients in the U.S. are discharged from the hospital with a primary or secondary diagnosis of ACS.

About XARELTO® (rivaroxaban)

XARELTO® belongs to a group of medicines called anticoagulants, and works by blocking the blood clotting Factor Xa, thereby reducing the tendency to form clots. In the U.S., XARELTO® is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) in people undergoing knee or hip replacement surgery, and for reducing the risk of stroke and systemic e
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Record Breaking $327 Million Verdict Upheld in Janssen Case and Request for New Trial Denied
2. Dr. Paul Janssen Award for Biomedical Research Issues Call for Nominations
3. Pharmacyclics Forms Pact to Develop and Commercialize PCI-32765 for Hematologic Cancers with Janssen Biotech, Inc.
4. Janssen Pharmaceuticals, Inc. Launches Online Tools on PrescribeResponsibly.com
5. Janssen Pharmaceuticals, Inc. Announces Definitive Agreement to Divest Ortho Dermatologics Division
6. Dr. Napoleone Ferrara Wins 2011 Dr. Paul Janssen Award for Biomedical Research
7. Janssen Products, LP Modifies Prescribing Information for PROCRIT® (Epoetin alfa) in Chronic Kidney Disease
8. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Voluntarily Recalls One Lot of RISPERDAL® Tablets and One Lot of Risperidone Tablets
9. Record Breaking $327 Million Verdict Announced in Janssen Case
10. MHPA Center for Best Practices Receives Sponsorship from Ortho-McNeil Janssen Pharmaceuticals, Inc. to Improve Medicaid Quality, Care Coordination for Serious Mental Illness
11. Lilly Makes an Irrevocable Offer to Acquire Janssen Animal Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... 2014 HeartWare International, Inc . (NASDAQ: ... miniaturized circulatory support technologies that are revolutionizing the treatment ... revenues for the fourth quarter of 2013 will be ... approximately $208 million. "Our full-year revenue growth ...
(Date:1/14/2014)... 14, 2014 InformEx, North America,s ... chemistry, will hold the 30 th edition of its ... Convention Center from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ... pharmaceutical, fine chemical and specialty chemical companies will take part ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... NEWTON, Mass., May 22, 2012  Halo Therapeutics, LLC, ... rare fibrotic diseases, announced today that it has ... foundations serving the muscular dystrophy patient community. Halo ... 2 study of HT-100, its lead drug candidate ...
... Company, a Medicare Part D provider with offices in ... in the arbitration between the company and ProCare, its ... following a suit against ProCare based on Fox,s allegations ... 2012, the U.S. District Court for the Northern District ...
Cached Medicine Technology:Halo Therapeutics Raises $1.1 Million to Expedite Phase 2 Study of HT-100 2Halo Therapeutics Raises $1.1 Million to Expedite Phase 2 Study of HT-100 3Judge Upholds $3.3 Million Judgment In Favor of Fox Insurance Company Against Former Pharmacy Benefit Manager 2
(Date:4/17/2014)... signs of chronic inflammation in non-cancerous prostate tissue may ... cancer than those with no inflammation, according to results ... Johns Hopkins Kimmel Cancer Center. , The link between ... with so-called high-grade prostate cancer those with a ... presence of the most aggressive and rapidly growing prostate ...
(Date:4/17/2014)... a study published today in PLOS Pathogens , ... malaria is common can mount an immune response to ... avoid repeated bouts of high fever and illness and ... bloodstream. The findings may help researchers develop future interventions ... malaria parasite. , Each year, approximately 200 million cases ...
(Date:4/17/2014)... In a review published in the April issue of ... The Feinstein Institute for Medical Research, says it,s time ... approach to treating sepsis, which kills millions ... Sepsis occurs when molecules released into the bloodstream to ... body. Inflammation is necessary for maintaining good health ...
(Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
(Date:4/17/2014)... By discovering a new mechanism that allows blood to ... UC Irvine and the Salk Institute have opened the ... stroke-induced brain damage. , A complex and devastating neurological ... primary reason for disability in the U.S. The blood-brain ... blood-borne material into the brain, causing the permanent deficits ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Study IDs new cause of brain bleeding immediately after stroke 2
... prevalent in Mali with 90% women getting circumcised in ... , ,The circumcision are performed by witch doctors ... million women worldwide have been subjected to genital mutilation ... awareness of the dangers of such practices making the ...
... Illinois at Urbana-Champaign have developed a simple, disposable sensor ... the performance of much more sophisticated laboratory instruments. ... for assessing uranium contamination in the environment, and the ... professor at Illinois and senior author of a paper ...
... of Veterinary Medicine have derived uniparental embryonic stem cells ... sperm - and, for the first time, successfully used ... in adult mice. Their findings demonstrate that ... organ and could provide a less controversial alternative to ...
... 340 grams of omega-3-rich seafood per week during pregnancy ... in the children, says a new study. ... of seafood consumption during pregnancy, which state women should ... avoid exposing the foetus to trace amounts of pollutants ...
... have come out with a device which is likely// ... bladder control issues. ,They have named ... urinary circuit in spinal cord which is responsible for ... to sustain continence. This device is extremely useful in ...
... lasercomb which promises hair growth in the scalp has been ... Lasercomb is manufactured by Lexington International LLC, a Florida based ... laser technology in a comb which when passed through the ... both men and women. The company’s website reveals that they ...
Cached Medicine News:Health News:DNA-based Detection of Heavy Metals 2Health News:'single–parent' stem cells to replace adult mice organ 2Health News:'single–parent' stem cells to replace adult mice organ 3Health News:Fish Intake Linked to Higher IQ in Offspring 2Health News:Bladder Pacemaker For Incontinence 2Health News:Bladder Pacemaker For Incontinence 3
... Product features of the Mastercycler ep ... Gradient blocks with SteadySlope technology ... a stand-alone device, a Mini-Satellite system, or ... ESP technology (Electronic Sample Protection) Optional motorized ...
... features of the Mastercycler ep Extremely ... blocks with SteadySlope technology Intuitive graphic ... device, a Mini-Satellite system, or a PC-controlled ... (Electronic Sample Protection) Optional motorized lid for ...
... The DNA Engine instrument is ... Unprecedented thermal uniformity and ... and block-to-block. This rugged ... cycler, it's a platform for new ...
... Start up kit. Includes configured Laptop PC ... 1 MultiBlock satellite thermal Cycler (non-robotic). ... User friendly software. Store/track run data. ... lid. Outstanding uniformity. Advanced control ...
Medicine Products: